3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
5
Neoplasms
3
Fallopian Tube Neoplasms
2
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Carcinogenesis
1
Brain Neoplasms
1
Interventions
Gemcitabine
87
Cisplatin
66
Cystectomy
38
pembrolizumab
34
Docetaxel
25
Nivolumab
24
durvalumab
21
Paclitaxel
19
Magnetic Resonance Spectroscopy
18
Radiotherapy
17
Mitomycin
17
Carboplatin
16
atezolizumab
15
Doxorubicin
14
Cystoscopy
14
BCG Vaccine
13
Surveys and Questionnaires
12
Standard of Care
12
avelumab
11
Sunitinib
10
tremelimumab
9
Transurethral Resection of Bladder
9
Ipilimumab
9
Filgrastim
9
Blood Specimen Collection
9
Specimen Handling
8
Neoadjuvant Therapy
8
Methotrexate
8
Methods
8
Early Intervention, Educational
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urinary Bladder Neoplasms
×
Monatide (IMS 3015)
×
Clear all
NCT04106115
2024-12-04
DURANCE
University College, London
Phase 1/2
Recruiting
64 enrolled